Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Amplia Therapeutics ( (AU:ATX) ) has issued an announcement.
Amplia Therapeutics Limited has announced the issuance of new unquoted equity securities, specifically options expiring on September 30, 2028, with an exercise price of $0.30. This move is part of an employee incentive scheme, which may enhance employee retention and motivation, potentially impacting the company’s operational dynamics and stakeholder interests positively.
The most recent analyst rating on (AU:ATX) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Amplia Therapeutics stock, see the AU:ATX Stock Forecast page.
More about Amplia Therapeutics
Amplia Therapeutics Limited operates in the biotechnology industry, focusing on the development of novel therapies for the treatment of cancer and fibrotic diseases. The company is engaged in advancing its pipeline of products to address unmet medical needs in these areas.
YTD Price Performance: 85.39%
Average Trading Volume: 7,254,682
Technical Sentiment Signal: Buy
Current Market Cap: A$82.69M
See more insights into ATX stock on TipRanks’ Stock Analysis page.